#4-41E. Unlocking the ABCs of Lupus: Overcoming Treatment Resistance (JAutoimmun, 2025)

Why do some patients with severe systemic lupus erythematosus (SLE) show limited responses to conventional B cell depletion therapies? This episode dives into "The role of age-associated B cells in systemic lupus erythematosus" to answer this pressing clinical question. The review outlines how age-associated B cells (ABCs), which abnormally expand in SLE, drive disease progression by producing pathogenic autoantibodies and inflammatory cytokines. The most striking finding discussed is the identification of the transcription factor ZEB2 as a definitive driver of ABC differentiation, presenting a potential breakthrough for addressing treatment-resistant B cell populations. However, when critically appraising this paper, listeners should note that many mechanistic insights, including the role of viral infections in ABC expansion, rely heavily on murine models, highlighting a need for more direct evidence in human SLE. For clinicians, understanding the unique pathways of ABCs is crucial, as it paves the way for novel, targeted therapeutic strategies that could overcome the limitations of current treatments like rituximab, ultimately reshaping how we manage refractory lupus in our daily practice.

Citation: Su Q-Y, Zheng X-X, Han X-T, Li Q, Gao Y-R, Zhang S-X, Li X-F. The role of age-associated B cells in systemic lupus erythematosus. Journal of Autoimmunity. 2025. DOI: 10.1016/j.jaut.2025.103433

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.